Physician profile
John Varmaa Wainwright
NPI 1811308372
$49,145.93
in general payments reported to CMS, 2019-2025
28 companies · $23K in 2025
The $23K reported for 2025 was more than what 91% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.76 · 2021: $622 · 2022: $14K · 2023: $8,941 · 2024: $3,295 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $9,361 · Travel and Lodging: $6,089 · Entertainment: $34.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,385.30 |
| Food and Beverage | $9,361.05 |
| Travel and Lodging | $6,088.91 |
| Entertainment | $34.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $14,737.53 | 2021-2025 | Excelsius Gps, Excelsiusgps Robotic Navigation System, Acp |
| Icotec Medical INC. | $7,941.84 | 2023-2025 | Vader Pedicle System 6.0, Screw, Carbon/Peek, Polyax., Fen., O 5.5 X 45 Mm, Kong-Tl Vbr, End Plate, Rectangular, M and Screw, 12 X 33 Mm, Vader Pedicle System, Rod, Carbon/Peek, Curved, 6.0 R450 X 200 Mm |
| Alphatec Spine, INC | $6,392.66 | 2022-2025 | Other - Miscellaneous, Invictus Open |
| Medtronic, INC. | $5,051.29 | 2022-2025 | Unid_pass, Intellis Adaptivestim, Mazor X System |
| Nuvasive, INC. | $3,868.18 | 2022-2023 | Xlif, Reline |
| Stryker Corporation | $2,430.41 | 2021-2023 | Everest Spinal System, Na, N/A |
| Baxter Healthcare | $2,327.85 | 2023 | Floseal |
| Si-Bone, INC. | $1,191.94 | 2022-2025 | |
| Cerapedics INC. | $731.62 | 2023-2025 | I-Factor Peptide Enhanced Bone Graft |
| Spineology INC. | $617.40 | 2024 | Optimesh Expandable Interbody Fusion System |
| Djo, LLC | $532.63 | 2023-2025 | Cmf |
| Arteriocyte Medical Systems, INC. | $499.82 | 2023-2024 | Magellan |
| Depuy Synthes Sales INC. | $370.22 | 2022-2025 | Symphony |
| Synthes Gmbh | $360.54 | 2021 | |
| Gt Medical Technologies, INC | $338.86 | 2025 | Gammatile |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $305.10 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Providence Medical Technology, INC. | $281.13 | 2024-2025 | |
| Sanara Medtech INC. | $217.61 | 2023 | Celleraterx |
| Centinel Spine, LLC | $186.75 | 2022 | |
| Amgen INC. | $148.74 | 2025 | |
| Alafair Biosciences, INC. | $148.14 | 2023 | Versawrap |
| Irras USA, INC. | $122.41 | 2024 | |
| Lifenet Health | $119.52 | 2023 | |
| Abbvie INC. | $76.18 | 2023 | Botox |
| Zimvie INC. | $63.44 | 2024 | |
| Orthofix Medical, INC. | $46.40 | 2023 | Cervical-Stim, Spinal-Stim |
| Augmedics INC. | $20.24 | 2024 | Xvision |
| Spinal Elements, INC. | $17.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wainwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.